Search

everythinglearnresearchcommunity

for

Search:↓

Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Axitinib treatment turned a man's grey hair back to black.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

A woman with a long-term skin condition developed a serious skin cancer that led to her death.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

A man's skin condition, pemphigus vulgaris, came back after he was treated with interleukin 2 for cancer.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

Different types of skin cells have unique genetic markers that affect how likely they are to spread cancer.

A man's adrenal insufficiency was caused by a pituitary tumor linked to kidney cancer.

Identical p53 gene mutations in different cancers suggest the need for careful treatment.

Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.

Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.

Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

miR-22 helps skin cancer grow and spread by activating specific cell signals.

A man with kidney tumors and lung cysts was diagnosed with Birt–Hogg–Dubé syndrome and treated successfully, with genetic testing confirming the diagnosis.

Skin cancer in sun-exposed areas is more likely to come back.

GLI1 RNA CISH effectively identifies basal cell carcinoma but is less specific for benign follicular tumors.

A 90-year-old woman's hand lesion was a rare, aggressive skin cancer treated successfully with surgery.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Researchers found a safe and effective way to pick genetically modified skin cells with high growth potential using CD24.